Breast Cancer Advisor: O'Regan - Cancer Therapy Advisor

Breast Cancer Advisor: O’Regan

Chapter 2

HER2-positive Metastatic and Triple-negative Cancer Treatments

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments for patients with HER2-positive, metastatic breast cancer, as well as those for triple-negative breast cancer. CDK inhibitors and everolimus are among the treatments used for patients with HER2-positive disease, though other drugs are being studied. Dr O’Regan also discusses current research on triple-negative cancer.

Chapter 3

Treatment-related Neuropathy and Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses treatment-related neuropathy, which is a common adverse event among patients being treated for breast cancer. Dr O’Regan discusses options for mitigating this side effect, which can be caused by multiple frequently-used treatments.

Chapter 4

Emerging Medicines in Breast Cancer Treatment

In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments that are being used for patients with breast cancer, including precision medicine for individualizing cancer treatment, as well as liquid biopsies.

Next hm-playlist in Breast Cancer